Wesley Yiu
Investor at Triphammer Ventures
New York, New York
Overview
Work Experience
Partner
2018 - Current
Alumni Ventures Group is a venture capital investment firm that manages fund families that invest in a portfolio of companies.
Raised $500,000.00 from Michael Bunning.
Partner
2023
Part of Alumni Ventures
Senior Principal
2021 - 2023
Principal
2019 - 2021
Senior Associate
2018 - 2019
Triphammer Ventures is a smart, simple way for Cornell alums and friends of the community to add venture capital to their portfolio.
Investor
2024
Operant provides security at cloud native scale.
Raised $13,000,000.00 from SineWave Ventures, Felicis, Massive, Calm Ventures, Alumni Ventures and Gaingels.
Investor
2024
Vertical SaaS for Construction Contract and Procurement
Raised $2,300,000.00 from Meridian Ventures, Lerer Hippeau, Laconia Ventures, Alumni Ventures, Redbud VC, The LegalTech Fund, MetaProp and Redbud VC.
Investor
2024
A powerful AI Analyst for your customers
Inventive is an AI agent platform that develops tools to help companies build smarter products together.
Raised $6,500,000.00 from Tokyo Black, Wing Venture Capital, Stratus Ventures and Alumni Ventures.
Investor
2024
Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.
Raised $115,500,000.00 from Cadence Healthcare Ventures, Boston Scientific, Norwest Venture Partners, Aphelion Capital, BioStar Capital and Alumni Ventures.
Investor
2024
Tabs is the first AI Driven Revenue Automation Platform for B2B Finance
Raised $37,000,000.00 from Gokul Rajaram, FOG Ventures, General Catalyst, Kiran Lingam, Imraan Ahmed, Greg Raiten, Zunaira Arshad, Primary Venture Partners and Lightspeed Venture Partners.
Investor
2024
Observe offers an observability cloud solution to accelerate the transformation of troubleshooting applications and resolving incidents.
Raised $307,000,000.00 from Snowflake Ventures, Sutter Hill Ventures, Madrona, Evolution Equity Partners, Alumni Ventures and Capital One Ventures.
Investor
2024
Investor
2024
CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases.
Raised $228,589,594.00 from CPP Investments, Sands Capital Ventures, Global Health Investment Corporation, Norwest Venture Partners, Breakout Ventures and Alumni Ventures.
Education
Bachelor of Science (BS)
2008 - 2011